Updated Oct 26, 10:24 PM · 60 sources analyzed
Key Takeaways
Incyte's INCB161734 showed durable pancreatic tumor responses at ESMO, but full numerical data remain unreleased — model updates must wait.
Nektar's NKTR-255 Phase 2/3 CAR-T support trial was terminated, narrowing the pipeline and raising questions about the IL-15 modality.
Sanofi's NK cell engager SAR443579 program in AML was also terminated, adding to a broader pattern of attrition in the NK engager class.
🏆 Winner
Incyte — INCB161734 durability signal in pancreatic cancer at ESMO supports late-stage advancement despite limited numerical disclosure.
📉 Loser
Nektar Therapeutics — termination of NKTR-255 Phase 2/3 in a high-profile post-CAR-T setting removes a key pipeline asset with no disclosed explanation.
🔭 Watch Next
Recursion Pharmaceuticals' REC-994 Phase 2 completion in cerebral cavernous malformation sets up a rare-disease data readout that will test the company's AI-driven drug discovery platform in a condition with no approved therapies.
Incyte's pancreatic cancer drug shows durable responses at ESMO
Incyte presented data at ESMO Madrid showing its targeted agent INCB161734, combined with chemotherapy, produced lasting tumor responses in a molecularly selected pancreatic cancer population. The company says the durability of response supports its earlier decision to advance the treatment into a later-stage study — though full numerical detail has not yet been released publicly. Pancreatic cancer remains one of oncology's most intractable targets, and any signal of durable disease control in a biomarker-selected subset will draw scrutiny from competitors and potential partners alike.
STAT News ↗Incyte
INCB161734 in Pancreatic cancer (molecularly selected)
Company reported lasting tumor responses in combination with chemotherapy in certain pancreatic cancer patients at ESMO Madrid. Full numerical data — including objective response rate (the share of patients whose tumors shrank), response duration, and p-values — have not been released; the company disclosed topline results without providing full numerical detail.
Why it matters
The company's decision to advance INCB161734 ahead of full data disclosure suggests internal confidence in the durability signal, but investors will need to see the complete response rate, duration curves, and patient selection criteria before underwriting a Phase 3 thesis. The critical question is how narrow the biomarker-selected population is — a tight selection can inflate response rates while shrinking the commercial addressable market.
What to watch
Watch for full dataset publication or presentation at a major oncology meeting in H1 2027, and any Phase 3 design announcement that will clarify biomarker eligibility criteria.
Nektar Therapeutics
NKTR-255 in Relapsed/refractory large B-cell lymphoma (post CAR-T)
The Phase 2/3 randomized, double-blind, placebo-controlled study of NKTR-255 versus placebo following CD19-directed CAR-T therapy was terminated. No efficacy or safety data were disclosed in the registry update; the termination reason has not been publicly detailed.
Why it matters
The termination of the NKTR-255 CAR-T support program eliminates what had been one of Nektar's more clinically rationale late-stage bets — IL-15 agonism to sustain CAR-T persistence is a biologically sound concept, so the discontinuation raises questions about whether the failure was efficacy-driven, safety-driven, or commercial. Investors will want clarity on which, as it affects how the broader IL-15 field is read.
What to watch
Watch for a company statement or SEC filing disclosing the specific reason for termination, and whether Nektar reallocates resources to remaining pipeline assets or pursues partnering.
Sanofi
SAR443579 in Acute myeloid leukemia and hematological malignancies
The Phase 1/2 study of SAR443579 — a natural killer cell engager (a bispecific antibody designed to activate NK immune cells against cancer) — in hematological malignancies was terminated. No efficacy or safety data were released alongside the registry status update.
Why it matters
NK cell engagers have struggled to translate preclinical promise into clinical results, and this termination adds to a pattern of attrition in the class. For Sanofi, which has been reshaping its oncology portfolio, the discontinuation may reflect a broader prioritization decision rather than a single-asset failure — but the market will read it as the latter without further context.
What to watch
Watch for Sanofi's next oncology pipeline update or R&D day for clarity on whether the NK engager modality is being exited entirely or whether successor assets are in development.
Recursion Pharmaceuticals
REC-994 in Cerebral cavernous malformation (a rare vascular brain lesion condition)
The Phase 2 randomized, double-blind, placebo-controlled study of REC-994 (200 mg and 400 mg) versus placebo in cerebral cavernous malformation has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data were disclosed in the registry update; full data are expected at a future medical meeting or publication.
Why it matters
Recursion has positioned REC-994 as a proof-of-concept for its AI-driven drug discovery platform in rare neurological disease — the data readout will matter both for the asset itself and as a test of whether the platform generates clinically actionable hypotheses. A positive outcome would be a rare-disease catalyst for a company whose investment thesis increasingly rests on platform credibility.
What to watch
Watch for Recursion to announce a data readout at a neurology conference or via press release in the coming months, which will be the first read on REC-994's efficacy in this indication.
Company reported lasting tumor responses in combination with chemotherapy in certain pancreatic cancer patients at ESMO Madrid. Full numerical data — including objective response rate (the share of patients whose tumors shrank), response duration, and p-values — have not been released; the company disclosed topline results without providing full numerical detail.
Why it matters
Durable responses in a biomarker-enriched pancreatic cancer cohort are rare enough that even a modest signal can justify late-stage investment and attract partnership interest in a space where the bar for excitement is low.
Analysis
The company's decision to advance INCB161734 ahead of full data disclosure suggests internal confidence in the durability signal, but investors will need to see the complete response rate, duration curves, and patient selection criteria before underwriting a Phase 3 thesis. The critical question is how narrow the biomarker-selected population is — a tight selection can inflate response rates while shrinking the commercial addressable market.
What to watch
Watch for full dataset publication or presentation at a major oncology meeting in H1 2027, and any Phase 3 design announcement that will clarify biomarker eligibility criteria.
The Phase 2/3 randomized, double-blind, placebo-controlled study of NKTR-255 versus placebo following CD19-directed CAR-T therapy was terminated. No efficacy or safety data were disclosed in the registry update; the termination reason has not been publicly detailed.
Why it matters
A terminated Phase 2/3 in CAR-T support narrows Nektar's pipeline and removes a potential differentiator in the competitive post-CAR-T maintenance space.
Analysis
The termination of the NKTR-255 CAR-T support program eliminates what had been one of Nektar's more clinically rationale late-stage bets — IL-15 agonism to sustain CAR-T persistence is a biologically sound concept, so the discontinuation raises questions about whether the failure was efficacy-driven, safety-driven, or commercial. Investors will want clarity on which, as it affects how the broader IL-15 field is read.
What to watch
Watch for a company statement or SEC filing disclosing the specific reason for termination, and whether Nektar reallocates resources to remaining pipeline assets or pursues partnering.
The Phase 1/2 study of SAR443579 — a natural killer cell engager (a bispecific antibody designed to activate NK immune cells against cancer) — in hematological malignancies was terminated. No efficacy or safety data were released alongside the registry status update.
Why it matters
The termination removes an early NK-cell engager asset from Sanofi's oncology pipeline, a setback in a modality that has faced repeated clinical challenges despite strong preclinical rationale.
Analysis
NK cell engagers have struggled to translate preclinical promise into clinical results, and this termination adds to a pattern of attrition in the class. For Sanofi, which has been reshaping its oncology portfolio, the discontinuation may reflect a broader prioritization decision rather than a single-asset failure — but the market will read it as the latter without further context.
What to watch
Watch for Sanofi's next oncology pipeline update or R&D day for clarity on whether the NK engager modality is being exited entirely or whether successor assets are in development.
The Phase 2 randomized, double-blind, placebo-controlled study of REC-994 (200 mg and 400 mg) versus placebo in cerebral cavernous malformation has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data were disclosed in the registry update; full data are expected at a future medical meeting or publication.
Why it matters
Completion of the only known placebo-controlled trial of a systemic therapy for cerebral cavernous malformation sets the stage for a pivotal data readout in a rare disease with no approved treatments.
Analysis
Recursion has positioned REC-994 as a proof-of-concept for its AI-driven drug discovery platform in rare neurological disease — the data readout will matter both for the asset itself and as a test of whether the platform generates clinically actionable hypotheses. A positive outcome would be a rare-disease catalyst for a company whose investment thesis increasingly rests on platform credibility.
What to watch
Watch for Recursion to announce a data readout at a neurology conference or via press release in the coming months, which will be the first read on REC-994's efficacy in this indication.
The Phase 2 study evaluating the efficacy and safety of RAP-219 in adult participants with bipolar I disorder has been marked Completed on ClinicalTrials.gov. No efficacy or safety data were disclosed in the registry update; full data are expected at a future medical meeting or publication.
Why it matters
Completion of this Phase 2 positions Rapport for a potential readout in bipolar I, a large and underserved indication where tolerability differentiation is often as important as efficacy.
Analysis
RAP-219 represents Rapport's effort to apply selective AMPA receptor modulation — a mechanism designed to achieve CNS activity with reduced off-target effects — to a broad psychiatric indication. The data readout will be watched carefully by CNS-focused investors to see whether the selectivity profile translates into a clean tolerability story alongside meaningful symptom reduction.
What to watch
Watch for Rapport to disclose top-line Phase 2 results via press release or at a psychiatry conference, likely in Q1 2027, which will determine whether the company pursues Phase 3 advancement.
Computational design yields two novel PDE4 inhibitors for plaque psoriasis
Researchers used computational modeling to design two new phosphodiesterase-4 (PDE4) inhibitors — a class of drugs that reduce inflammation by blocking a specific enzyme — intended to improve on existing agents for plaque psoriasis.
Why it matters
If the in silico design approach generates compounds with better selectivity or tolerability than current PDE4 inhibitors like apremilast, it could inform next-generation topical or systemic psoriasis therapies with reduced gastrointestinal side effects.
Analysis
The PDE4 space in dermatology is competitive but not saturated — Pfizer's crisaborole and Lilly's roflumilast cream have demonstrated the commercial viability of topical PDE4 inhibition, and any computationally guided compound showing improved selectivity could find a partnering audience. The immediate bar is preclinical validation; this preprint has not yet been peer-reviewed.
What to watch
Watch for in vitro and in vivo validation data in peer-reviewed publication, which will determine whether these candidates advance toward IND-enabling studies.
GSK completes Phase 2 of multi-component Shigella vaccine in African infants
GlaxoSmithKline's Phase 2 study of its multicomponent Shigella vaccine candidate (altSonflex1-2-3) evaluating immune response and safety in African infants has been marked Completed on ClinicalTrials.gov; no immunogenicity or efficacy data have been released from the registry update.
Why it matters
Shigella causes hundreds of thousands of deaths annually in low- and middle-income countries, predominantly in children under five, and no licensed vaccine currently exists — Phase 2 immunogenicity data from a multi-serotype candidate could define the path to a pivotal efficacy trial.
Analysis
GSK is one of the few large pharma players with active Shigella vaccine programs, and completion of this Phase 2 positions it as a leader in a neglected pediatric infectious disease space that is increasingly attracting GAVI and BARDA funding. The immunogenicity readout will be the key gating factor for whether a Phase 3 efficacy study is feasible in a commercially challenging but globally impactful indication.
What to watch
Watch for GSK to publish or present Phase 2 immunogenicity and safety data at a vaccinology conference in 2027, which will determine the shape of any Phase 3 program.
United Therapeutics completes Phase 3 of inhaled treprostinil in idiopathic pulmonary fibrosis
United Therapeutics' Phase 3 study (RIN-PF-303) evaluating inhaled treprostinil against placebo for change in forced vital capacity (a measure of lung function) in idiopathic pulmonary fibrosis has been marked Completed on ClinicalTrials.gov; no outcome data are yet available from the registry update.
Why it matters
Treprostinil (Tyvaso) is already approved for pulmonary hypertension associated with interstitial lung disease — a positive IPF result would represent a significant label expansion into a disease with limited treatment options and high unmet need.
Analysis
If RIN-PF-303 delivers a positive FVC result, United Therapeutics would have a rare opportunity to extend an established and commercially proven inhaled prostacyclin into pure IPF — a market currently anchored by nintedanib and pirfenidone. The outcome will also inform whether the prostacyclin pathway plays a meaningful role in IPF pathophysiology beyond its known pulmonary vascular effects.
What to watch
Watch for United Therapeutics to report Phase 3 top-line results within the next one to two quarters, with an eye on whether the FVC benefit reaches the threshold for regulatory filing.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.